CN118043350A - 抗vegf a和vegf c双特异性抗体及其用途 - Google Patents

抗vegf a和vegf c双特异性抗体及其用途 Download PDF

Info

Publication number
CN118043350A
CN118043350A CN202280055810.XA CN202280055810A CN118043350A CN 118043350 A CN118043350 A CN 118043350A CN 202280055810 A CN202280055810 A CN 202280055810A CN 118043350 A CN118043350 A CN 118043350A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
antibody
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280055810.XA
Other languages
English (en)
Chinese (zh)
Inventor
黎一鸣
胡思怡
陈炳良
周帅祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN118043350A publication Critical patent/CN118043350A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280055810.XA 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途 Pending CN118043350A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021109320787 2021-08-13
CN202110932078 2021-08-13
PCT/CN2022/111717 WO2023016516A1 (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Publications (1)

Publication Number Publication Date
CN118043350A true CN118043350A (zh) 2024-05-14

Family

ID=85200580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280055810.XA Pending CN118043350A (zh) 2021-08-13 2022-08-11 抗vegf a和vegf c双特异性抗体及其用途

Country Status (7)

Country Link
US (1) US20250002570A1 (https=)
EP (1) EP4386004A4 (https=)
JP (1) JP2024529119A (https=)
CN (1) CN118043350A (https=)
AU (1) AU2022327397A1 (https=)
CA (1) CA3229250A1 (https=)
WO (1) WO2023016516A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4663202A1 (en) * 2023-02-10 2025-12-17 Innovent Biologics (Suzhou) Co., Ltd. Pharmaceutical preparation containing anti-vegfa and anti-vegfc bispecific binding protein
WO2025250739A1 (en) * 2024-05-31 2025-12-04 Janssen Biotech, Inc. Chimeric antigen receptor with spacer domains derived from human igg

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
WO2011071577A1 (en) * 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
EP2558122A4 (en) * 2010-04-15 2014-03-05 Vegenics Pty Ltd COMBINATION TREATMENT WITH VEGF-C ANTAGONISTS
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JP5987057B2 (ja) * 2011-07-27 2016-09-06 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｆｃドメインと融合した抗ｖｅｇｆ単一可変ドメイン
KR102131370B1 (ko) * 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
WO2016172485A2 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用

Also Published As

Publication number Publication date
AU2022327397A1 (en) 2024-03-14
WO2023016516A1 (zh) 2023-02-16
JP2024529119A (ja) 2024-08-01
EP4386004A4 (en) 2025-08-13
EP4386004A1 (en) 2024-06-19
US20250002570A1 (en) 2025-01-02
CA3229250A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
TWI855236B (zh) 抗cd47/抗pd-l1抗體及其應用
US20220235123A1 (en) Synthetic antibodies against vegf and their uses
US20220185875A1 (en) Bispecific antibody specifically bound to vegf and ang2
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
CN114573695A (zh) 抗人b7-h3抗体及其应用
EP4349861A1 (en) Bispecific binding molecule binding vegf and ang2 and use thereof
KR20240004860A (ko) 디엘엘3에 대한 결합 분자 및 이의 용도
CN114907479A (zh) 抗cd112r抗体及其用途
US20260009804A1 (en) Antibodies that bind to natively folded myocilin
US20250002570A1 (en) Anti-vegf a and vegf c bispecific antibodies and use thereof
CN118791606A (zh) 双特异性抗体及其应用
JP7804295B2 (ja) 二機能性融合タンパク質およびその用途
JP2025539445A (ja) Ｖｅｇｆおよびａｎｇ２に結合する二重特異性結合分子を含む製剤およびその使用
IL311153A (en) Bispecific antibody and its use
WO2024002145A1 (zh) 结合il-17a和il-17f的抗体分子及其应用
WO2025113639A1 (zh) 抗gdf15的抗体及其方法和用途
CN118791607A (zh) 双特异性抗体及其应用
TW202302641A (zh) 針對IL-13Rα2的抗體及其應用
HK40104627A (zh) 双功能融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination